1. 474PA novel biomarker combination and its association with resistance to chemotherapy combinations with bevacizumab: First results of the PERMAD trial. (23rd October 2018) Authors: Seufferlein, T; Lausser, L; Stein, A; Prager, G; Kasper, S; Niedermeier, M; Müller, L; Kubicka, S; König, A-O; Büchner-Steudel, P; Wille, K; Perkhofer, L; Hann, A; Berger, A W; Arnold, D; Kestler, H; Ettrich, T J Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Association of modifiable factors with the development of physical fitness of Austrian primary school children: A 4-year longitudinal study. Issue 8 (18th April 2022) Authors: Ruedl, G; Niedermeier, M; Posch, M; Kirschner, W; Wirnitzer, K; Cocca, A; Greier, K Journal: Journal of sports sciences Issue: Volume 40:Issue 8(2022) Page Start: 920 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. The bacterial effector protein YopM is a selfdelivering immune therapeutic agent that reduces inflammation in rheumatoid arthritis. (4th April 2011) Authors: Bertrand, J; Rüther, C; Scharnert, J; Niedermeier, M; Schmidt, A; Pap, T Journal: Annals of the rheumatic diseases Issue: Volume 69(2010)Supplement 2 Page Start: A47 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗